You are here

gene therapy

Krystal looks to Phase III as stock soars on data for gene therapy

Krystal looks to Phase III as stock soars on data for gene therapy

BioCentury

Krystal Biotech

Flag link:

Pharmacquired: Is $11B enough to secure Sanofi's spot in hemophilia?

Pharmacquired: Is $11B enough to secure Sanofi's spot in hemophilia?

Biopharma Dive

Flag link:

Sanofi to ax 466 jobs, step up focus on cancer, gene therapy R&D

Sanofi to ax 466 jobs, step up focus on cancer, gene therapy R&D

Fierce Biotech

immuno-oncology

Flag link:

'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops

'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops

Endpoints

Bristol-Myers Squibb

Flag link:

What Bluebird Bio Gets Wrong In Pricing For Its $1.8 Million Drug

What Bluebird Bio Gets Wrong In Pricing For Its $1.8 Million Drug

Forbes

beta thalassemia

Flag link:

Rocket begins patient dosing in phase 1 trial of RP-A501 in Danon disease

Rocket begins patient dosing in phase 1 trial of RP-A501 in Danon disease

Pharmaceutical Business Review

Rocket Pharmaceuticals

Flag link:

Bluebird delays gene therapy launch to 2020, citing manufacturing tweaks

Bluebird delays gene therapy launch to 2020, citing manufacturing tweaks

Biopharma Dive

drug manufacturing

Flag link:

Sanofi Genzyme deserts gene therapy developer Voyager Therapeutics

Sanofi Genzyme deserts gene therapy developer Voyager Therapeutics

Endpoints

Voyager Therapeutics

Flag link:

bluebird offers installment payments for Zynteglo gene therapy

bluebird offers installment payments for Zynteglo gene therapy

Pharmaforum

outcome-based pricing

beta thalassemia

Flag link:

Cue the M&A chatter: UniQure is scouting for a buyout deal as gene therapy field sizzles — report

Cue the M&A chatter: UniQure is scouting for a buyout deal as gene therapy field sizzles — report

Endpoints

Flag link:

Gene therapy costs, manufacturing keeping CBER head 'up at night'

Gene therapy costs, manufacturing keeping CBER head 'up at night'

Biopharma Dive

drug manufacturing

Flag link:

The gene therapy era has arrived. So have the challenges.

The gene therapy era has arrived. So have the challenges.

Biopharma Dive

Flag link:

Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy?

Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy?

Motley Fool

Duchenne Muscular Dystrophy

Vertex Pharmaceuticals

CRISPR Therapeutics

Flag link:

Vertex sets sights on DMD gene therapy, joining crowded field

Vertex sets sights on DMD gene therapy, joining crowded field

Biopharma Dive

Vertex Pharmaceuticals

CRISPR Therapeutics

Flag link:

Patients, payers await pricing plans for bluebird's first approved gene therapy

Patients, payers await pricing plans for bluebird's first approved gene therapy

BioCentury

beta thalassemia

Flag link:

Bluebird Bio’s Gene Therapy for Blood Disease Wins European Approval

Bluebird Bio’s Gene Therapy for Blood Disease Wins European Approval

Xconomy

beta thalassemia

Flag link:

Is the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous?

Is the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous?

Motley Fool

Flag link:

Amicus widens UPenn gene therapy collaboration

Amicus widens UPenn gene therapy collaboration

Biopharma Dive

Amicus Therapeutics

Flag link:

How BioMarin May Revolutionize the Hemophilia Treatment Market

How BioMarin May Revolutionize the Hemophilia Treatment Market

Motley Fool

Flag link:

Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range

Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range

Yahoo/Reuters

Flag link:

Pages